IDXX

SEC source: 0001567619-21-004323 · doc1.xml · nonDerivative · entry 3

Hunt Nimrata · CIK 0001800619 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,998

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-004323 · doc1.xml · nonDerivative · entry 2

Hunt Nimrata · CIK 0001800619 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,872

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-004323 · doc1.xml · nonDerivative · entry 1

Hunt Nimrata · CIK 0001800619 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,784

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 14 shares purchased under the Issuer's Employee Stock Purchase Plan on December 31, 2020.

SEC source: 0001567619-21-004088 · doc1.xml · derivative · entry 4

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,046 shares

Expires 2027-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Not applicable.

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable on May 3, 2018.

SEC source: 0001567619-21-004088 · doc1.xml · nonDerivative · entry 2

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,321

SEC source: 0001567619-21-004088 · doc1.xml · nonDerivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,367

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 13

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · 2021 Szostak IDEXX GRAT

Disclosed balance after: 10,217

F7 · ownership.nature: The reporting person is the settlor and trustee of the 2021 Szostak IDEXX GRAT (the "GRAT"). The GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein.

SEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 11

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust of M. Anne Szostak

Disclosed balance after: 10,217

SEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 10

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · 2020 Szostak IDEXX GRAT

Disclosed balance after: 0

SEC source: 0001567619-21-004615 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 652,737

SEC source: 0001567619-21-002490 · doc1.xml · derivative · entry 15

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,902 shares

Expires 2026-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · price: Not applicable.

F9 · derivative.exercise_date: Grant of option to buy 5,902 shares of IDEXX Laboratories, Inc. common stock that became exercisable in one installment on May 4, 2016.

SEC source: 0001567619-21-002490 · doc1.xml · derivative · entry 14

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,974 shares

Expires 2024-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · price: Not applicable.

F8 · derivative.exercise_date: Grant of option to buy 2,987 shares of IDEXX Laboratories, Inc. common stock that became exercisable in one installment on May 7, 2015 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 12

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust of M. Anne Szostak

Disclosed balance after: 0

SEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 9

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust of M. Anne Szostak

Disclosed balance after: 0

F6 · price: Represents the weighted average price of the shares sold ranging from a low of $492.31 to a high of $492.46 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 8

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust of M. Anne Szostak

Disclosed balance after: 300

F5 · price: Represents the weighted average price of the shares sold ranging from a low of $491.05 to a high of $492.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 7

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust of M. Anne Szostak

Disclosed balance after: 1,400

F4 · price: Represents the weighted average price of the shares sold ranging from a low of $490.02 to a high of $491.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 6

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust of M. Anne Szostak

Disclosed balance after: 4,799

F3 · price: Represents the weighted average price of the shares sold ranging from a low of $489.01 to a high of $490.01 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 5

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust of M. Anne Szostak

Disclosed balance after: 9,085

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $488.00 to a high of $489.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 4

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust of M. Anne Szostak

Disclosed balance after: 11,876

F1 · ownership.nature: The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust.

SEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 3

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 2

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,876

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 1

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,974

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-002133 · doc1.xml · nonDerivative · entry 1

JUNIUS DANIEL M · CIK 0001094159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,875

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($6,250.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001567619-21-002132 · doc1.xml · nonDerivative · entry 1

ESSIG STUART · CIK 0001187574 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 993

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($20,000.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001567619-21-002131 · doc1.xml · nonDerivative · entry 1

COLLINS Asha · CIK 0001832272 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($20,000.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001567619-20-020611 · doc1.xml · derivative · entry 2

COLLINS Asha · CIK 0001832272 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 358

Underlying: Common Stock · 358 shares

Expires 2030-11-30

F4 · price: Not applicable.

F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vests in one installment on May 6, 2021.

SEC source: 0001567619-20-020611 · doc1.xml · derivative · entry 1

COLLINS Asha · CIK 0001832272 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109

Underlying: Common Stock · 109 shares

Expires not disclosed

F1 · security: This equity grant represents pro rata equity compensation earned by the reporting person as a non-employee Director from her election to the IDEXX Laboratories, Inc. Board of Directors on November 11, 2020 until the 2021 annual meeting of stockholders.

F2 · derivative.exercise_price: Each deferred stock unit ('DSU') represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These DSUs will fully vest on the date of the 2021 annual meeting of stockholders or May 6, 2021, whichever event occurs earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F4 · price: Not applicable.

F2 · derivative.exercise_date: Each deferred stock unit ('DSU') represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These DSUs will fully vest on the date of the 2021 annual meeting of stockholders or May 6, 2021, whichever event occurs earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F2 · derivative.expiration_date: Each deferred stock unit ('DSU') represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These DSUs will fully vest on the date of the 2021 annual meeting of stockholders or May 6, 2021, whichever event occurs earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001567619-20-020567 · doc1.xml · derivative · entry 3

TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,227

Underlying: Common Stock · 12,801 shares

Expires 2026-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Not applicable.

F3 · derivative.exercise_date: Grant of option to buy 22,028 shares of IDEXX Laboratories, Inc. common stock that vests in five annual installments beginning February 14, 2017.

SEC source: 0001567619-20-020567 · doc1.xml · nonDerivative · entry 2

TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,922

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $456.00 to a high of $457.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-020567 · doc1.xml · nonDerivative · entry 1

TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,723

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 16 shares purchased under the Issuer's Employee Stock Purchase Plan on September 30, 2020.

SEC source: 0001567619-20-020565 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 686,857

SEC source: 0001567619-20-020983 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 660,737

F1 · balance_after: This amendment is being filed to correct an error in the amount of securities reported as beneficially owned directly by the reporting person.

SEC source: 0001567619-20-019312 · doc1.xml · derivative · entry 4

HENDERSON REBECCA M · CIK 0001254748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,902 shares

Expires 2026-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Not applicable.

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable on May 4, 2017.

SEC source: 0001567619-20-019312 · doc1.xml · nonDerivative · entry 3

HENDERSON REBECCA M · CIK 0001254748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,696

SEC source: 0001567619-20-019312 · doc1.xml · nonDerivative · entry 2

HENDERSON REBECCA M · CIK 0001254748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,553

SEC source: 0001567619-20-019312 · doc1.xml · nonDerivative · entry 1

HENDERSON REBECCA M · CIK 0001254748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,598

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-018938 · doc1.xml · derivative · entry 20

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,256 shares

Expires 2025-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F14 · price: Not applicable.

F13 · derivative.exercise_date: Grant of option to buy 628 shares of IDEXX Laboratories, Inc. common stock that vested on the fifth anniversary of the date of grant without giving effect to Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-20-018938 · doc1.xml · derivative · entry 19

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,612 shares

Expires 2024-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F14 · price: Not applicable.

F12 · derivative.exercise_date: Grant of option to buy 806 shares of IDEXX Laboratories, Inc. common stock that vested on the fifth anniversary of the date of grant without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-20-018938 · doc1.xml · nonDerivative · entry 18

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,413

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-018938 · doc1.xml · nonDerivative · entry 17

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,157

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-019112 · doc1.xml · nonDerivative · entry 6

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Indirect · by Estony McKeon Family, LLC

Disclosed balance after: 18,050

F5 · price: Represents the weighted average price of the shares sold ranging from a low of $477.86 to a high of $478.26 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-019112 · doc1.xml · nonDerivative · entry 5

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Indirect · by Estony McKeon Family, LLC

Disclosed balance after: 21,050

F4 · price: Represents the weighted average price of the shares sold ranging from a low of $476.51 to a high of $477.61 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-019112 · doc1.xml · nonDerivative · entry 4

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Indirect · by Estony McKeon Family, LLC

Disclosed balance after: 23,150

SEC source: 0001567619-20-019112 · doc1.xml · nonDerivative · entry 3

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Indirect · by Estony McKeon Family, LLC

Disclosed balance after: 23,450

F3 · price: Represents the weighted average price of the shares sold ranging from a low of $474.38 to a high of $475.32 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-019112 · doc1.xml · nonDerivative · entry 2

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Indirect · by Estony McKeon Family, LLC

Disclosed balance after: 26,788

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $473.42 to a high of $474.32 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-019112 · doc1.xml · nonDerivative · entry 1

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Indirect · by Estony McKeon Family, LLC

Disclosed balance after: 28,029

F1 · price: Represents the weighted average price of the shares sold ranging from a low of $472.36 to a high of $473.36 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-019111 · doc1.xml · nonDerivative · entry 5

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 709,991

F5 · price: Represents the weighted average price of the shares sold ranging from a low of $471.16 to a high of $471.49 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-019111 · doc1.xml · nonDerivative · entry 4

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 711,691

F4 · price: Represents the weighted average price of the shares sold ranging from a low of $470.12 to a high of $471.03 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-019111 · doc1.xml · nonDerivative · entry 3

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 713,379

F3 · price: Represents the weighted average price of the shares sold ranging from a low of $469.112 to a high of $470.11 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-019111 · doc1.xml · nonDerivative · entry 2

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 715,278

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $467.87 to a high of $468.69 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.